NCT01173627已完成1 期
An Open-Label, Randomized, Two-Period, Crossover Study to Evaluate the Bioequivalence of an Oral Transmucosal Test Troche Formulation of Fentanyl Citrate (400 mcg) Compared to an Equivalent Dose of a Commercially Available Reference Drug Product (Actiq 400 mcg, Cephalon, Inc.) in Normal Human Subjects Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Mallinckrodt
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- Average bioequivalence is established if the 90% confidence interval on the ratio of formulation averages for AUCt, AUCinf, and Cmax are contained in the interval [80%, 125%].
研究概览
简要总结
The purpose of this study was to evaluate the oral bioequivalence of the Mallinckrodt test fentanyl citrate oral transmucosal 400 mcg troche compared to Actiq 400 mcg (Cephalon, Inc.) under fasting conditions.
详细描述
Fentanyl is an opioid analgesic with pharmacological effects similar to morphine. Fentanyl interacts predominately with the opioid µ-receptor. In clinical settings, fentanyl exerts its principal pharmacologic effects on the central nervous system. The fentanyl citrate oral transmucosal troche, Actiq (Cephalon, Inc.), is indicated only for the management of breakthrough cancer pain in patients with malignancies who are already receiving and who are tolerant to prior therapy for their underlying persistent cancer pain.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males or non-pregnant, non-lactating females, 18 years of age or older with a minimum body weight of 120 pounds and a body mass index (BMI) between 19 and 29 inclusive.
- •Female subjects must be postmenopausal for at least one year, surgically sterile, or using a reliable method of contraception (oral, transdermal, or injectable hormonal contraceptive; condom with spermicide; IUD; abstinence, etc.) for at least 30 days prior to and for the duration of study participation.
- •Normal, healthy status confirmed by required screening assessments.
- •Subjects must be able to provide written consent and agree to abide by the study requirements.
- •Subjects must be able to demonstrate they understand and can perform the dosing procedure correctly using a placebo troche at check-in to Period 1.
排除标准
- •If female, a positive pregnancy test at any time during the study, pregnant, lactating, or likely to become pregnant during the study.
- •Female subjects of childbearing potential who have not used adequate forms of birth control within 30 days of dosing.
- •History of conditions that might contraindicate or require caution be used in the administration of fentanyl or naltrexone, including: renal impairment, hepatobiliary or pancreatic disease, gastrointestinal obstruction, cardiac disease, obstructive pulmonary disease, acute or severe bronchial asthma, hypercarbia, elevated intracranial pressure, depleted blood volume, paralytic ileus, or hypersensitivity or idiosyncratic reaction to fentanyl, naltrexone, or any opioids.
- •History of any drug allergy, hypersensitivity, or intolerance which would compromise the safety of the subject or the study.
- •History of chronic alcohol, drug, or narcotic abuse, chronic use of tranquilizers, sedatives, aspirin, antibiotics, or other medications.
- •History of malignancy, stroke, or diabetes; cardiac, renal, liver, and pulmonary disease.
- •History of anxiety, tension, severe agitation, psychiatric disorders, psychosis, or mental depression requiring hospitalization, psychotherapy, and/or medication.
- •History or diagnosis of epilepsy or other seizure disorder.
- •History of abdominal and/or pelvic surgery within the last 5 years, except elective surgical sterilization.
- •History of acute abdominal conditions or gastrointestinal disease including, but not limited to, peptic ulcer, diverticulitis, bowel obstructions, adhesions, ileus, gastritis, and chronic diarrhea.
- •Subjects presenting with acute illness.
- •Administration of any other investigational drug during the 30 days prior to study entry.
- •Subjects who have smoked or used nicotine-containing products within 6 months prior to study entry.
- •Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days prior to study entry, including that withdrawn during the conduct of any other clinical study.
- •Positive test results for HIV, hepatitis B, or hepatitis C.
- •Positive test results for drugs of abuse or alcohol.
- •Subjects who have taken prescription drugs, except hormonal contraception, within 14 days or over-the-counter medications (including herbal preparations) within 7 days prior to study drug administration except for standard daily dose multivitamins, which are excluded after check-in to Period
- •Any subject experiencing adverse events to the -13 and/or -1 hour doses of naltrexone, that in the investigator's opinion, are indicative of possible previous opioid use/abuse, or that would prevent tolerance of additional doses of naltrexone, will be withdrawn from the study prior to dosing with fentanyl.
- •Subjects with dental braces or partial dentures.
- •Subjects presenting with a history of gum disease.
研究组 & 干预措施
A - Test fentanyl citrate 400 mcg troche
Experimental
Test fentanyl citrate 400 mcg troche
干预措施: Test fentanyl citrate 400 mcg troche (Drug)
B - Actiq 400 mcg
Active Comparator
Actiq 400 mcg
干预措施: Actiq 400 mcg (Drug)
结局指标
主要结局
Average bioequivalence is established if the 90% confidence interval on the ratio of formulation averages for AUCt, AUCinf, and Cmax are contained in the interval [80%, 125%].
时间窗: 30 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy ParticipantsHealthyNCT02617758Janssen Research & Development, LLC56
已完成
4 期
Transdermal Patch CVD 2000: The Effect of Heat on Fentanyl Release From Fentanyl TDSs in Healthy AdultsPeer Review, ResearchNCT02486016University of Maryland, Baltimore10
已完成
1 期
A Single Dose, Cross-over Bioequivence Study Comparing Galantamine IR (Immediate Release) Table and Galantmine OS (Oral Solution) in Healthy VolunteersPharmacokineticsNCT00645554Xian-Janssen Pharmaceutical Ltd.2
已完成
不适用
Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting ConditionsBioavailabilityNCT02138396INSYS Therapeutics Inc12
已完成
3 期
Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic PainChronic PainNCT00813488Cephalon213